drugset / Trial / NCT00765947

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

NCT00765947

Phase 4 Completed 256 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension. (defined as mean sitting Systolic Blood Pressure \[msSBP\] ≥ 140 mmHg and \< 180 mmHg and/or mean sitting Diastolic Blood Pressure \[msDBP\] ≥ 90 and \<110 mmHg).

Timeline

Start
2008-09
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Subject Amlodipine Other / unclassified 10 mg
Subject Hydrochlorothiazide Unknown 25 mg